Loyal: solo founder's $5.1M seed for dog-longevity drugs

Loyal is a biotech company developing drugs to extend dog lifespan and healthspan, an early bet in what its founder calls consumer bio: drug discovery aimed at pet owners who pay out of pocket.

That dog owners will pay for drugs extending pets' lives — a venture-scale consumer-bio market fundable on founder-market fit before any team or science existed.

$5.1M seed (closed January 2020); ~$6M more by May 2021

Celine Halioua, a neuroscience graduate, former Oxford PhD candidate and two-year VC, was not planning to start a company when a campfire conversation about making dogs live longer reached Greg Rosen, an investor building a pet-genomics thesis. Regular coffees through summer 2019 turned the idea into Loyal (raised under the name Celevity); when Rosen offered a term sheet, she decided to leave her job and go out for her first round.

She raised for an idea and a deck — no co-founder, team or lab data — targeting Silicon Valley and NYC tech and biotech funds while skipping traditional East Coast biotech VCs, whose pre-lead drug deals she considered far more dilutive. After Rosen and Longevity Fund committed about half the round on terms they set together, she ran a CRM of 157 investors, compressed about 65 pitch meetings into six weeks, and 17 investors (roughly 11%) converted; the first 80% of the round subscribed in about two weeks, the last 20% took three, and the round closed oversubscribed at $5.1M in January 2020. She deliberately prioritized speed and partner fit over dilution, iterating an 80-page deck into a ~20-slide main story with a detailed appendix, and later closed roughly another $6M.

Biotech VCs doubted the pet market could support a $1B+ company; tech VCs loved the market but needed time on the science — the cap table ended up mostly tech.

Compressed timelines manufactured urgency: 65 conversations inside about six weeks produced fast yes/no's and stopped the deal dying of time, though it cost investors who wanted a longer courtship.

She traded dilution for capital velocity deliberately: in biotech, money in the coffers correlates with success, and solo-founder flexibility let her oversubscribe on terms she liked.

Founder-market fit substituted for team and data: domain expertise, an Oxford PhD background, a VC network and a longevity community made an idea-and-deck raise credible to 17 investors.

Fundraising is engineerable even from an outsider starting point: CRM the market, compress the timeline, iterate the pitch — and deliberately trade dilution for speed and partner fit.

As of 2021-05-27, Loyal (raised under the name Celevity) had closed roughly $11M in total — the $5.1M January 2020 seed plus about $6M more — and was developing drugs against a specific protein intended to extend dog lifespan and healthspan, with no product or revenue yet disclosed. The founder's essay, written to document the playbook for founders 'who do not fit the pattern', was the company's main public artifact and reached the Hacker News front page on the day it was submitted.